Ascletis Pharma Inc. — Audit Report / Information 2017

Jul 10, 2018

PHIP

	Ascletis Pharma Inc.
	YOU SHOULD READ THE WARNING IN THE DOCUMENT.

 

	Warning Statement
	Important
	EXPECTED TIMETABLE
	CONTENTS
	SUMMARY
	DEFINITIONS
	GLOSSARY OF TECHNICAL TERMS
	FORWARD-LOOKING STATEMENTS
	RISK FACTORS
	WAIVERS AND EXEMPTION FROM COMPLIANCE WITH THE LISTING RULES AND COMPANIES (WINDING UP AND MISCELLANEOUS PROVISIONS) ORDINANCE
	INFORMATION ABOUT THIS DOCUMENT AND THE [REDACTED]
	DIRECTORS AND PARTIES INVOLVED IN THE [REDACTED]
	CORPORATE INFORMATION
	INDUSTRY OVERVIEW
	REGULATIONS
	HISTORY, REORGANIZATION AND CORPORATE STRUCTURE
	BUSINESS
	DIRECTORS AND SENIOR MANAGEMENT
	RELATIONSHIP WITH CONTROLLING SHAREHOLDERS
	SUBSTANTIAL SHAREHOLDERS
	SHARE CAPITAL
	FINANCIAL INFORMATION
	FUTURE PLANS AND USE OF PROCEEDS
	[REDACTED]
	STRUCTURE OF THE [REDACTED]
	HOW TO APPLY FOR [REDACTED]
	APPENDIX I: ACCOUNTANTS’ REPORT
	APPENDIX II: UNAUDITED PRO FORMA FINANCIAL INFORMATION
	APPENDIX III: SUMMARY OF THE CONSTITUTION OF OUR COMPANY AND CAYMAN ISLANDS COMPANIES LAW
	APPENDIX IV: STATUTORY AND GENERAL INFORMATION
	APPENDIX V: DOCUMENTS DELIVERED TO THE REGISTRAR OF COMPANIES AND AVAILABLE FOR INSPECTION